<DOC>
	<DOCNO>NCT02251847</DOCNO>
	<brief_summary>To evaluate efficacy safety combination therapy rosuvastatin ezetimibe versus monotherapy rosuvastatin hypercholesterolemia patient</brief_summary>
	<brief_title>The Efficacy Safety Combination Therapy Rosuvastatin Ezetimibe Versus Monotherapy Rosuvastatin Hypercholesterolemia Patients</brief_title>
	<detailed_description>To evaluate efficacy safety combination therapy rosuvastatin ezetimibe versus monotherapy rosuvastatin hypercholesterolemia patient</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Hypercholesterolemic patient Has history hypersensitivity HMGCoA reductase inhibitor Ezetimibe</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>cholesterol</keyword>
</DOC>